The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase
AstraZeneca has upgraded a 2020 alliance with Fusion Pharma focusing on radioconjugate therapies for cancer, opting to buy the firm outright in a deal worth around $2 bill
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment